Welcome to our dedicated page for Acutus Medical news (Ticker: AFIB), a resource for investors and traders seeking the latest updates and insights on Acutus Medical stock.
Acutus Medical, Inc. (OTC: AFIB) drives innovation in cardiac electrophysiology through its specialized left-heart access devices and strategic partnerships. This page serves as the definitive source for verified news and press releases directly from the company.
Investors and healthcare professionals will find timely updates on manufacturing agreements, product developments, and operational milestones. Our curated collection ensures access to essential information about AFIB's evidence-based solutions for complex arrhythmias, including its collaboration with Medtronic.
Key updates cover regulatory progress, clinical advancements, and financial developments while maintaining compliance with disclosure standards. All content undergoes rigorous verification to provide reliable insights into the company's focused electrophysiology strategy.
Bookmark this page to stay informed about Acutus Medical's latest achievements in medical device innovation and operational efficiency improvements. Check regularly for authoritative updates from the source.
Acutus Medical, focusing on arrhythmia management, announced a corporate restructuring aimed at improving financial stability. This includes a planned reduction in force and strategic realignment to enhance console utilization and procedure volume. The company expects to save $23-25 million annually and reduce quarterly cash burn by 30-40% by the end of 2022. Additionally, Acutus reported preliminary revenues of $4.2-4.4 million for Q4 2021, a significant increase from $2.6 million in Q4 2020. Full-year revenues are projected at $17.1-17.3 million, up from $8.5 million in 2020.
Acutus Medical (Nasdaq: AFIB) announced its participation in the 27th Annual AF Symposium, showcasing its AcQMap 3D Imaging and Mapping System and other technologies. Physicians from prestigious institutions will present live cases using Acutus technology to demonstrate its adaptability in treating various arrhythmias. Abstracts will highlight the efficiency of the AcQMap system, alongside the AcQCross Universal Transseptal Crossing System. This symposium unites global electrophysiology leaders to discuss advancements in atrial fibrillation management.
Acutus Medical has launched the AcQForce PFA-CE clinical study to evaluate its novel Pulsed Field Ablation (PFA) catheter and noncontact mapping technology for treating atrial fibrillation (AF). Initiated in the Czech Republic, the study aims to assess safety and performance in up to 60 patients. The AcQBlate Force catheter uniquely combines RF and PFA therapies while utilizing the AcQMap 3D Imaging System. Acutus aims to enhance treatment precision and patient outcomes through advanced technologies.
Acutus Medical reported a third quarter 2021 revenue of $4.6 million, up from $3.2 million year-over-year, driven by increased procedure volumes and sales of AcQMap products. The company achieved a significant three-fold growth in left heart access revenues and initiated a groundbreaking software release for mapping. However, the gross margin remained at -86%, worsening from -62% the previous year due to product mix issues. Operating expenses decreased slightly to $23.2 million, with a net loss of $28.5 million. Looking ahead, full-year sales are projected between $17.0 million and $17.5 million.
Acutus Medical (AFIB) is set to announce its third-quarter 2021 financial results on November 11, 2021. The company will host a conference call at 1:30 PM PT / 4:30 PM ET, where it will discuss financial outcomes and recent developments. Interested investors can join by dialing specific numbers or through the investor relations website. Acutus specializes in arrhythmia management, providing innovative electrophysiology products aimed at improving diagnosis and treatment efficiency.
Acutus Medical, listed as AFIB, announced Niamh Pellegrini's appointment to its Board of Directors, effective August 10, 2021. Pellegrini brings over 20 years of healthcare experience, currently serving as Chief Commercial Officer at Nevro, Inc. Her proven track record in business growth and product launches is expected to benefit Acutus in the electrophysiology sector. Concurrently, Shahzad Malik will step down from the board after a decade of service. Acutus focuses on innovating arrhythmia management through advanced technologies.
Acutus Medical, Inc. (AFIB) reported a remarkable revenue increase of $4.7 million for Q2 2021, significantly up from $1.1 million in Q2 2020, driven by higher procedure volumes and AcQMap console sales. The installed base of AcQMap consoles rose to 68 units. The company received US Investigational Device Exemption for its AcQBlate system. Despite a net loss of $28.7 million, cash reserves reached $81.2 million. The full-year revenue guidance remains at $22 million to $30 million, amidst ongoing COVID-19 challenges.
Acutus Medical (Nasdaq: AFIB) has announced FDA clearance and CE Mark approval for its software suite, AcQMap 8, which enhances the mapping of complex atrial arrhythmias. Key features include the AcQTrack algorithm that identifies abnormal conduction patterns and the SlowZone Locator, which maps areas of slow conduction. Clinical data shows targeting these patterns increases sinus rhythm success rates. AcQMap 8 integrates with existing systems, advancing arrhythmia treatments and improving patient outcomes.
Acutus Medical, a company focused on arrhythmia management, announced its participation in the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 17, 2021. This event will feature management meetings aimed at engaging with investors.
The company is dedicated to improving diagnosis and treatment of cardiac arrhythmias through innovative technologies. Established in 2011 and based in Carlsbad, California, Acutus has a wide range of electrophysiology products that enhance physician capabilities in treating patients.
Acutus Medical, a company specializing in arrhythmia management, will release its financial results for Q2 2021 on August 12, 2021. A conference call will follow at 1:30 PM PT / 4:30 PM ET to discuss these results and recent highlights. Acutus aims to transform the diagnosis and treatment of cardiac arrhythmias through innovative products and technologies, enhancing the efficiency of healthcare providers. Founded in 2011 and based in Carlsbad, California, the company continues to expand its global sales presence.
